Jennifer Tousignant's most recent trade in Viridian Therapeutics Inc was a trade of 10,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Aug. 19, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Viridian Therapeutics Inc | Ms. Jennifer Tousignant | Chief Legal Officer | 19 Aug 2026 | 10,000 | 114,072 | - | - | Stock Option (Right to Buy) | ||
| Viridian Therapeutics Inc | Ms. Jennifer Tousignant | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 24.50 per share. | 19 Aug 2026 | 10,000 | 0 (0%) | 0% | 24.5 | 245,000 | Common Stock |
| Viridian Therapeutics Inc | Ms. Jennifer Tousignant | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.41 per share. | 19 Aug 2026 | 10,000 | 10,000 (0%) | 0% | 14.4 | 144,100 | Common Stock |
| Viridian Therapeutics Inc | Ms. Jennifer Tousignant | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 24.50 per share. | 19 Aug 2026 | 4,212 | 0 (0%) | 0% | 24.5 | 103,194 | Common Stock |
| Viridian Therapeutics Inc | Ms. Jennifer Tousignant | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.19 per share. | 03 Mar 2026 | 1,675 | 3,494 (0%) | 0% | 30.2 | 50,568 | Common Stock |
| Viridian Therapeutics Inc | Ms. Jennifer Tousignant | Chief Legal Officer | 02 Mar 2026 | 119,300 | 119,300 | - | - | Stock Option (Right to Buy) | ||
| Viridian Therapeutics Inc | Ms. Jennifer Tousignant | Chief Legal Officer | 02 Mar 2026 | 23,850 | 23,850 | - | - | Restricted Stock Units | ||
| Viridian Therapeutics Inc | Ms. Jennifer Tousignant | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2026 | 5,169 | 5,169 (0%) | 0% | - | Common Stock | |
| Viridian Therapeutics Inc | Ms. Jennifer Tousignant | Chief Legal Officer | 02 Mar 2026 | 5,169 | 15,510 | - | - | Restricted Stock Units | ||
| Viridian Therapeutics Inc | Ms. Jennifer Tousignant | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.32 per share. | 02 Mar 2026 | 1,724 | 3,445 (0%) | 0% | 29.3 | 50,548 | Common Stock |
| Viridian Therapeutics Inc | Ms. Jennifer Tousignant | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 31.16 per share. | 31 Dec 2025 | 2,272 | 0 (0%) | 0% | 31.2 | 70,796 | Common Stock |
| Viridian Therapeutics Inc | Ms. Jennifer Tousignant | Chief Legal Officer | 03 Mar 2025 | 124,072 | 124,072 | - | - | Stock Option (Right to Buy) | ||
| Viridian Therapeutics Inc | Ms. Jennifer Tousignant | Chief Legal Officer | 03 Mar 2025 | 20,679 | 20,679 | - | - | Restricted Stock Units | ||
| Viridian Therapeutics Inc | Ms. Jennifer Tousignant | Chief Legal Officer | 12 Feb 2024 | 290,000 | 290,000 | - | - | Stock Option (Right to Buy) |